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A short history of PNI
he first evidence suggesting an interaction
between the brain and the immune system came from
studies performed 80 years ago by Russian investigators.
Derived directly from a Pavlovian perspective on the con-
ditioning of behavioral and physiological responses,a con-
ditioned stimulus (CS) was repeatedly paired with injec-
tions of foreign proteins.Subsequent exposure to the CS,
alone, was purported to induce antibody production in
addition to a conditioned increase in a variety of non-
specific defense responses.
1As this research attracted very
little attention outside the Soviet Union,the commonly
accepted beginning of research in the field of psycho-
neuroimmunology (PNI) is associated with the experi-
ments of Ader, who was studying taste aversion condi-
tioning in rats in the 1970s.Conditioned animals that were
reexposed to a CS,previously paired with the immuno-
suppressive effects of cyclophosphamide showed an atten-
uated antibody response to sheep red blood cells.
2 The
results of these initial experiments demonstrated that the
immune system was subject to classical conditioning.
A more complex research direction in the field of PNI
was the study of behavioral influences on immunity,start-
ing in the 1950s with the research on stress and infectious
disease.
3 During the 1970s,Besedovsky was beginning to
systematically investigate the neuroendocrine–immune
system network with his studies on the effects of immune
responses on neural and endocrine function.
4 Felten
described the direct contact of noradrenergic sympathetic
nerve fibers with lymphocytes and macrophages.
5 He
showed that these nerve fibers were localized in specific
compartments of lymphoid organs,forming close,synap-
tic-like neuroeffector junctions with T lymphocytes and
macrophages.
6These “hard-wired”connections between
the brain and the immune system have since been shown
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Recent research has overcome the old paradigms of the
brain as an immunologically privileged organ, and of the
exclusive role of neurotransmitters and neuropeptides as
signal transducers in the central nervous system. Growing
evidence suggests that the signal proteins of the immune
system—the cytokines—are also involved in modulation of
behavior and induction of psychiatric symptoms. This article
gives an overview on the nature of cytokines and the pro-
posed mechanisms of immune-to-brain interaction. The role
of cytokines in psychiatric symptoms, syndromes, and disor-
ders like sickness behavior, major depression, and schizo-
phrenia are discussed together with recent immunogenetic
findings.
Dialogues Clin Neurosci. 2003;5:139-153.to be a major route for behavioral and central cytokine
influences on immune function.They are,thus,a corner-
stone for a mechanistic understanding of the signaling
between the nervous system and immune system.
All these investigations demonstrated the influence of
the central nervous system (CNS) on the immune func-
tion. However, this is only half the truth, as the
brain–immune interaction is bidirectional.The old para-
digm of the brain as an immunologically privileged organ
may have inhibited the research of the immune system’s
action on brain and behavior.Meanwhile,it is commonly
accepted that immune cells enter the brain even under
normal,nonpathological conditions,and that all kinds of
brain cells—neurons,glial and endothelial cells—are sen-
sitive to the transmitters of the immune system: the
cytokines.
Direct evidence for the neural activities of cytokines was
first obtained after injections of various cytokines system-
ically or into the cerebral ventricles (intracerebroventric-
ular [ICV]).These studies established that cytokines can
activate the hypothalamus-pituitary-adrenal (HPA) axis,
7-9
induce fever,
10 prolong slow-wave sleep,
11 reduce food
12 and
water intake,
13 and decrease motility.
14These effects were
evident not only in experimental animal, but also in
humans who received cytokine injections for cancer 
treatment.
15,16 The most tested cytokine with regard to
brain–immune interactions is interleukin-1 (IL-1),
although other cytokines such as the tumor necrosis fac-
tor alpha (TNF-α),
17,18 interferon (IFN),
19,20 IL-2,
21,IL-6,
22
and IL-12
23 can all induce one or several of the above
responses.
A large number of studies have investigated the ways in
which the cytokines influence brain function.Although
there are still a lot of open questions,the following sec-
tions will try to give a short overview of the current
knowledge of this part of PNI.
Cytokines
Nomenclature
The term cytokine defines a large group of nonenzymic
proteins that act as hormones.Their actions, as well as
their target cell populations,are both diverse and over-
lapping.Once released into the environment,cytokines
traverse small distances to ligate their high-affinity recep-
tors via either autocrine or paracrine fashion.Upon lig-
ation of the cytokine receptor,a signaling cascade is trig-
gered resulting in an alteration in gene transcription by
the target cell.
The pleiotropic features of cytokines have led to a con-
fusing nomenclature because they were frequently named
for their biological activity.It therefore repeatedly hap-
pened that a single cytokine was described by several
names.Another problem in the nomenclature of cytokines
emerged from their redundancy of action. In the 1970s,
two terms were introduced:the term cytokine defined the
large group of protein transmitters of the immune system.
The term interleukin tried to list all known cytokines in
numerical order.At the time this article was written,the
list of ILs ended at IL-27.
24 Unfortunately,some historical
groups like the IFNs,TNF,lymphotoxins (LT),transform-
ing growth factor beta (TGFβ),leukocyte inhibitory fac-
tor (LIF), and most of the colony stimulating factors
(CSFs) remained to be known by their old names.
25This is
particularly confusing,for example,the IFNs are divided
into two totally different groups:type I interferons (IFN-
α,IFN-β,and others) and type II interferon IFN-γ.On the
other hand, the new group of chemokines was defined
after IL-8 and several related cytokines were determined
to form a distinct cytokine family.
According to the complexity and diversity of the
cytokines, there are several possibilities for grouping
them.They can be grouped by structural similarities,clus-
tered chromosomal localization of their encoding genes,
or principally similar functional features.
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Selected abbreviations and acronyms
BBB blood–brain barrier
COX cyclooxygenase-2
CS conditioned stimulus
CSF colony-stimulating factor
CVO circumventricular organ
HPA hypothalamus-pituitary-adrenal (axis)
5-HT serotonin (5-hydroxytryptamine)
ICV intracerebroventricular
IDO indoleamine-2,3-dioxygenase
IFN interferon
IL interleukin
LPS lipopolysaccharide
LT lymphotoxin
MD major depression
PNI psychoneuroimmunology
TGF  transforming growth factor beta
Th T helper (cell)
TNF-  tumor necrosis factor alphaStructure
The typical cytokine is a glycosylated monomeric peptide
of about 150 amino acids.Others are homodimers (eg,IL-5,
M-CSF) or homotrimers (TNF-α and LT-α), or het-
erodimers (IL-12) or heterotrimers (LT-α/β).
26 Three-
dimensional structure studies have shown that many oth-
erwise nonhomologous cytokines adopt similar
conformations.These structural features of some cytokines
permit their grouping into families.Members of the large
IL-2/IL-4 family (including IL-2 to IL-7,IL-9,IL-11,IL-12
p35,IL-13,IL-15,type I and type II IFNs,and CSFs) share
a common tertiary architecture characterized by bundles
of four antiparallel α-helices in a spatially similar arrange-
ment.
26-28
Two important cytokine families show distinct structures:
•The IL-1 family,consisting of IL-1α,IL-1β,IL-1 recep-
tor antagonist (IL-1ra),and IL-18,is characterized by a
β-trefoil structure.
26 IL-1α and IL-1β exert identical
actions via binding to a single 80-kDa cell surface recep-
tor (IL-1RI) and an accessory protein (AcP).
29 IL-1βand
IL-18 are formed as biologically inactive precursors that
are cleaved by the enzyme ICE (caspase 1).
30 IL-1ra is
a highly specific,competitive antagonist of IL-1RI,block-
ing all actions of IL-1 by inhibiting the association
between IL-1RI and AcP.
30 Four other members of this
family have recently been identified,but their biological
activity—especially with regard to their actions on the
CNS—remains to be elucidated.
31
•Another structurally similar cytokine family is that of
the TNFs including TNF-α, TNF-β, LT-β, Fas ligand
(CD90L),CD40 ligand,TNF-related apoptosis-induc-
ing ligand (TRAIL), and several other TNF ligand
superfamily members.
32The characteristic structure of
this family is a β-jellyroll.
26 Members of the TNF fam-
ily act as trimers,most of which are membrane-bound
and so are quite distinct in their properties from the
other cytokines.
33
Clustered chromosomal localization of cytokines
The cytokines are not members of a single gene super-
family.Remarkably few similarities have been noted in
their primary nucleotide or amino acid sequences,and
their genes are,for the most part,scattered throughout
the genome.However,some chromosomal regions where
cytokine coding genes are clustered are known. Most
interestingly,some of these chromosomal regions seem
to be associated with psychiatric disorders, especially
schizophrenia.
Chromosome 1
One cluster of genes coding for members of the IL-10 fam-
ily is located on chromosomal regions 1q32.These are the
cytokines IL-10,IL-19,IL-20,and IL-24.
34This region is of
major interest in genetic schizophrenia research,as several
linkage studies identified a susceptibility locus for schizo-
phrenia there.
35-37 Indeed, a recent study points to the 
IL-10 gene itself as a susceptibility gene for schizophrenia.
38
Chromosome 2
With exception of IL-18,the members of the IL-1 family
are encoded by closely linked genes on the long arm of
chromosome 2.
31An association of polymorphisms in the
genes coding for IL-1α, IL-1β, and IL-1ra with schizo-
phrenia was reported by Katila and colleagues.
39
Although this finding was not replicated,another group
described bifrontal temporal gray matter volume deficits
and generalized white matter tissue deficits in schizo-
phrenia patients who were carriers of a distinct poly-
morphism in the IL-1β gene.
40
Chromosome 5
The cytokine gene cluster on chromosomal region 
5q23-35 contains genes coding for IL-3,IL-4,IL-5,IL-9,
IL-12 p40,IL-13,GM-CSF,and others.
26This is of partic-
ular interest,as linkage studies pointed to a possible sus-
ceptibility locus for schizophrenia in this chromosomal
region.
41The same region was recently identified as con-
taining the susceptibility gene for Crohn’s disease.
42
Chromosome 6
The genes coding for three members of the TNF family,
TNF-α,TNF-β,and LT-β,are located in an immunologi-
cally important region: the HLA-III region, which is
embedded between the HLA-II and the HLA-I region on
the short arm of chromosome 6.Again,genome scans have
indicated a linkage of this chromosomal region with schiz-
ophrenia.
43 Boin and colleagues reported the association
of a functional single nucleotide polymorphism in the
TNF-α gene with schizophrenia,
44 but a replication study
performed by our group could not confirm this finding.
45
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The type I IFNs are encoded on chromosomal region 9p22.
This cluster contains about 15 closely linked functional
IFN-α and IFN-ω genes in addition to a single IFN-β
gene.
46All members of the IFN-α/β family (IFN-α,IFN-β,
IFN-ω,and IFN-τ) show at least 30% homology in their
amino acid sequence.
25 No conclusive data are available
indicating a susceptibility gene for a psychiatric disorder in
this chromosomal region.
Functional concepts
Cytokines are most commonly grouped by their func-
tional similarities,although this kind of categorization is
highly arbitrary with regard to their pleiotropy.One of
the most prominent concepts used to discriminate two
distinct ways that the specific immune system can react
on environmental stimuli is the classification of T helper
1 (Th1) and T helper 2 (Th2) cell diversity.This classifi-
cation is based on the cytokine production patterns of 
T helper cells and reflects the polarization of the immune
answer to either a cell-mediated (Th1) or a humoral
(Th2) immune response.
33
Th1 cells mainly produce IFN-γ, IL-2, IL-12, IL-18, and
TNF-β,while Th2 cells principally secrete IL-4,IL-5,IL-6,
IL-10,IL-13,and TGFβ.TNF-α and IL-10 are commonly
characterized as Th2-like cytokines, although they are
synthesized by both Th1 and Th2 cells.
47,48 IL-12 and IL-4
are essential for the development of Th1 and Th2,respec-
tively.
49The Th1 system promotes cell-mediated immune
responses against intracellular pathogens,whereas the
Th2 system helps B cell maturation and promotes
humoral immune responses against extracellular
pathogens.Th1 and Th2 cytokines antagonize each other
in promoting their own type of response, while sup-
pressing the other type of helper cell.Which system will
dominate over the other depends on the relative timing
and ratio of IL-4 to IFN-γ and IL-12.
50-52 Figure 1 may
help to understand the balance between Th1 and Th2.
Such a polarized development of T cells happens not only
on the peripheral level,but also in the CNS.Although ini-
tiation of T-cell responses is unlikely to occur within the
CNS,T cells and monocytes will be massively recruited if
pathogens are placed into the cerebral ventricles.
53
Perivascular macrophages,owing to their location close to
the blood–brain barrier (BBB), can stimulate T cells to
proliferate and secrete Th1 cytokines.
54 Following extrava-
sation into the CNS parenchyma,T cells also interact with
intrinsic CNS cells,particularly microglia and astrocytes.
53
Microglia progressively acquire a clear-cut macrophage
phenotype in response to CNS injuries,
55 and can induce
the production of Th1 cytokine IL-12
56,57 and of Th2
cytokines such as IL-10 and TGFβ.
53Astrocytes are also
potential sources of TGFβ,which inhibits MHC II (major
histocompatibility complex II) and ICAM-1 (intercellular
adhesion molecule 1) expression in macrophage/microglia.
58
Microglia and astrocytes also secrete chemokines that may
affect the recruitment of Th1 and Th2 cells.In sum,a com-
plex network between microglia,astrocytes,and T cells is
involved in the balance between Th1 and Th2 systems,
which in turn might have impact on immune responses
within the CNS.
How do cytokines act on the CNS?
Five ways for cytokine signals to enter the brain
One of the major reasons why the brain has long been
defined as an immunologically privileged organ is the
presence of a tight barrier between the brain and the
periphery:the BBB.To our current knowledge,there are
five pathways via which cytokine signals may cross the
BBB.
Transport across the BBB
There is evidence for an active, saturable, and specific
transport system for certain cytokines across the BBB.By
the use of radiolabeled cytokines in animal experiments,
cytokines like IL-1,TNF-α,and IL-2 were demonstrated
to be transported across the BBB.
59-62These experiments
suggest that active transport plays a significant role in get-
ting cytokines across the BBB.One limitation,however,
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Figure 1. The balance between Th1 (cell-mediated) and Th2 (humoral)
response of the adaptive (specific) immune system. IL, interleukin;
IFN-γ, interferon gamma; Th1, T helper 1; Th2, T helper 2.
Cellular Immune
response
Humoral
Th1 cells Th2 cells
IL-2
IFN-γ
IL-4
IL-10is that the absorption of labeled cytokines into the brain
tissue may not reflect the transport of cytokines across the
BBB,but the binding of cytokines to the BBB.Some data
show that the majority of intravenously (IV) infused radi-
olabeled IL-1α can be found on brain endothelial cells,
63
or on the surface and pinocytotic vesicles of the brain
endothelia shortly after injection.
64
Passage of circumventricular organs
The second pathway is that cytokines may affect the CNS
at the circumventricular organs (CVOs),which possess a
leaky BBB.The CVOs are midline structures bordering the
3rd and 4th ventricles and are the only areas of the brain
that are outside the BBB.CVOs are characterized by their
small size,high permeability,and fenestrated capillaries.
These barrier-deficient areas are recognized as important
sites for communicating with the cerebrospinal fluid and
between the brain and peripheral organs via blood-borne
products.CVOs include the following structures
65,66:
• Pineal gland,which is known as the regulatory organ of
the circadian rhythm because it produces the hormone
melatonin from the amino acid tryptophan.
• Median eminence of the hypothalamus, which arises
behind the optic chiasma and is continuous with the
pituitary stalk;it communicates with the cerebrospinal
fluid.
• Subfornical organ,which is positioned under the fornix
and is one of the “sensory CVOs”responsible for main-
taining body fluid balance.
• Area postrema (AP), which is a CVO close to the
nucleus of the solitary tract,part of the brain-stem bor-
dering the fourth ventricle.The AP is another “sensory
CVO” involved in body fluid homeostasis. It is also
thought to play a role in emesis and vomiting.
• Subcommissural organ,which contacts the third ven-
tricle covering the posterior commissure.It comprises
a complex of neurosecretory ependymal cells known to
secrete various glycoproteins into the cerebrospinal
fluid.The functional significance of these glycoproteins
has not yet been determined.
• Organum vasculosum of the lamina terminalis (OVLT),
which is a CVO close to the hypothalamic thermoreg-
ulatory center.
• The intermediate and neural lobes of the pituitary are
sometimes also cited as CVOs.
Lesions of the OVLT suppressed intraperitoneal (IP)
lipopolysaccharide (LPS)–induced fever
67,68 and removal
of AP–blocked IL-1-induced c-fos expression in the par-
aventricular nucleus,
69 indicating the important role of
these CVOs in transmitting the peripheral cytokines into
the brain.However,there are also controversial results,
showing the opposite effect.
70,71 The discrepant results
may be attributable to the extent of the lesion and the
different doses of LPS and IL-1 used in these studies.
Altogether, it seems that low doses LPS and IL-1 may
specifically affect the CVOs and high doses of LPS and
IL-1 may gain access to CNS at other sites.
72
Transmission via the vagus nerve
The third pathway for cytokines to engage the CNS is the
vagus nerve. Numerous studies have been published
demonstrating the involvement of vagus nerve in periph-
eral cytokine-induced CNS responses. One of the first
observations was that peripheral LPS-induced hyper-
algesia can be blocked by vagotomy,indicating that affer-
ent vagal pathways innervate specific regions of the brain
as a key connection between peripheral cytokines and
the CNS.
73 Others reported the role of the vagus nerve in
inducing fever,
74 activating the HPA axis,depleting nor-
epinephrine in the hypothalamus,
75 prolonging slow-wave
sleep,
76 and suppressing food-motivated behavior.
77Thus,
there is major evidence that vagal afferents are impor-
tant for conveying signals generated from IP injection of
low doses of LPS. The role of vagal afferents is more
important for the behavioral depression that develops in
response to peripheral immune stimuli than for the
induction of fever and activation of the HPA axis.
78
De novo synthesis by BBB cells
The fourth pathway is that peripheral immune stimuli
may induce the production of cytokines by cells of the
BBB, which then secret cytokines into the brain
parenchyma. In situ hybridization studies showed that
the cells of the BBB respond to peripheral immune stim-
ulation by producing IL-1,
79 IL-6,
80 and TNF-α.
81 Thus,
during systemic immune challenge, production of
cytokines by cells of the BBB may result in widespread
cytokine activity in the entire CNS.This is consistent with
a report that the IL-1 bioactivity can be found in all brain
regions after high-dose peripheral LPS injection.
82
Local action of cytokines at many brain sites may actu-
ally be mediated via the receptors on endothelial cells.
This binding induces another important effect of periph-
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143eral cytokines on cells of the BBB: the induction of
cyclooxygenase-2 (COX-2), a rate-limiting enzyme of
prostaglandin synthesis.Predominantly IL-1 and TNF-α
induce the expression of COX-2 in endothelial cells of
the BBB.
83,84
As many cytokine-induced CNS effects can be blocked
by COX inhibitors,
85,86 the cytokine-induced COX-2 activ-
ity in BBB cells may represent a central mechanism of
cytokine–CNS interaction.
Infiltrating leukocytes
Finally,it has to be considered that cytokines may enter
the brain via infiltrating leukocytes. It has long been
known that leukocytes may enter the brain under both
normal and pathological conditions.
87 In normal brain,
scattered and random crossing of the BBB by leukocytes
provide immune surveillance for the CNS.
88 Under
pathological conditions such as bacterial meningitis,acti-
vated leukocytes expressing inflammatory cytokines may
infiltrate the brain.
89,90 Additionally, CNS action of
cytokines may weaken the BBB,promoting an increased
infiltration of cytokine producing leukocytes.
Summary
The above mechanisms for the entrance of cytokines into
the brain highlight the limitations of measuring periph-
eral levels of cytokines in neuropsychiatric disorders.
Cytokine levels in the blood (ie,serum or plasma) may
reflect the systemic immune status and have been estab-
lished as useful clinical markers in septic shock,inflam-
matory disorders, or cancers,
91 but cannot conclusively
clarify the cytokine expression within the CNS.
Cytokine and cytokine receptor expression in the brain
The specificity of the response to cytokines is provided
by their receptors.Thus the expression of cytokine recep-
tors is necessary for signal transmission of the cytokines
entering the brain.Table I lists some selected cytokines
and their receptors that are expressed within the CNS.
Cytokine–neurotransmitter interactions
As the known effects of cytokines on the brain physiol-
ogy are extremely numerous and complex,we will just
give a few examples.
The effect of IFNs on neurons starts very early during
brain development,where they regulate neuronal migra-
tion and differentiation.
92 In vitro and in vivo studies
showed the modulating effect of IFNs on the production
of prolactin
93 and—of particular interest regarding psy-
chopathology—on the catecholaminergic,dopaminergic,
serotonergic,and glutamatergic neurotransmitter systems,
eg, the induction of transcriptional activity of the sero-
tonin (5-hydroxytryptamine [5-HT]) transporter.
94-97
TNF-α regulates the secretion of norepinephrine in the
brain.
98 Peripheral administration of TNF-α induces the
cerebral tryptophan content
99 and the synthesis of 5-HT
and dopamine.
100
There is experimental evidence that IL-1 can activate the
5-HT transporter thereby increasing the reuptake of 
5-HT from the synaptic cleft.
101 Furthermore, IL-1
enhances nonrapid eye movement (NREM) sleep and
activates the serotonergic system.
102 It has also been
reported that the NREM sleep enhancement induced by
IL-1 is partially inhibited by brain 5-HT depletion,
103 sug-
gesting that this IL-1 effect is partly mediated by the
serotonergic system. Observations that the biological
activities of IL-1 and 5-HT overlap to a large extent sug-
gest that interactions between these two systems may be
relevant to the manifestation of behavior under a variety
of conditions.In contrast to IL-1,the Th2 cytokine IL-10
reduces NREM sleep.
104
IL-2 can affect gene expression, neuronal activity, and
neurotransmitter release in brain regions subserving
sleep,memory and cognition,locomotion,and neuroen-
docrine function.IL-2 modulates the neurotransmission
of acetylcholine, dopamine, and norepinephrine in a
biphasic manner.
105 It appears to be a potent and specific
regulator of neurotransmission in frontal cortex, hip-
pocampus,striatum,and hypothalamus.
106
IL-6 is produced by neurons,astrocytes,and microglia.
107
This cytokine promotes neuronal differentiation and sur-
vival,
108 and modulates the neurotransmitter systems
summarized above.
109-111 Several studies have investigated
the influence of IL-6 on the production, release, and
metabolism of 5-HT. Peripherally administered IL-6
increases the concentrations of tryptophan and the 5-HT
metabolite 5-hydroxyindole acetic acid (5-HIAA) in the
brain,
112-114 and it has been proposed that the interaction
between IL-6 and brain 5-HT is a complex process.
115
Recent studies have demonstrated a new type of neural
activity of cytokines.IL-1 appears to act on neurons in
hippocampus and amygdala to inhibit long-term poten-
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116,117 A contrary
effect was demonstrated for TNF-α.Astrocytes continu-
ously release TNF-α to control synaptic strength.The
group led by Beattie has demonstrated that TNF-α
induces the expression of glutamatergic receptors of the
AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole pro-
prionate) type on neuronal axons.
118 Inhibition of the
TNF-α signal by specific antibodies or soluble receptors
lead to a reduced AMPA receptor expression. These
cytokine activities may be involved in the ability of
cytokines to alter the neural processes of learning.
119,120
Besides the direct action of cytokines on brain cells, a
biochemical link between cytokines and 5-HT is pro-
vided by the IFN-γ–controlled tryptophan metabolism.
The essential amino acid tryptophan is the precursor of
two distinct metabolism pathways,leading to the prod-
ucts 5-HT or kynurenine (Figure 2). The enzyme
indoleamine-2,3-dioxygenase (IDO) metabolizes trypto-
phan to kynurenine,which is then converted to quinolinic
acid by the enzyme kynurenine hydroxylase.Both IDO
and kynurenine hydroxylase are induced by IFN-γ.The
activity of IDO is an important regulatory component in
the control of lymphocyte proliferation.
121 It induces a
halt in the lymphocyte cell cycle due to the catabolism of
tryptophan.
122The Th2 cytokines IL-4 and IL-10 inhibit
the IFN-γ–induced tryptophan catabolism by IDO.
123The
enzyme IDO is located in several cell types including
monocytes and microglial cells.
124 Thus, an IFN-γ–
induced, IDO-mediated decrease in CNS tryptophan
availability may lead to a serotonergic deficiency.
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Table I. Expression of some selected cytokines and their receptors on neurons and glial cells. Th, T helper cell; C, cytokine; R, receptor; IFN, interferon;
TNF-α, tumor necrosis factor alpha; IL, interleukin; AIDS, acquired immune deficiency syndrome; CNS, central nervous system; HPA, hypothal-
amus-pituitary-adrenal; BBB, blood–brain barrier; ACTH, adrenocorticotropic hormone.
Cytokine Th1/Th2 type Immune activity C and R  C and R 
expression expression
on neurons on glial cells
IFN-α Not exactly  Antiviral, antiparasitic, antiproliferative activities; C inducible C, R
classifiable standard therapy for hairy cell leukemia, metastasizing
renal carcinoma, other tumors, AIDS-associated Kaposi 
sarcomas, and viral infections
IFN-γ Th1 Antiviral, antiparasitic, antiproliferative activities R C, R
TNF-α Not exactly  Causes cytolysis and cytostasis of many tumor cell lines;  R C, R
classifiable prothrombotic; induces synthesis of prostaglandin E2; 
mediates cachexia in tumor patients; involved in septic shock
IL-1 Th1 Important mediator of inflammatory reactions;  C, R C, R
antiproliferative and cytocidal activities on certain tumor cell 
types; stimulation of Th cells to secrete IL-2 and of B cells 
to produce immunoglobulins; enhances synthesis of 
prostaglandin E2; modulates the electrophysiological behavior 
of neurons; directly affects the CNS as an afferent signal 
modulating the release of a number of hormones; 
activates the HPA axis
IL-2 Th1 Proliferation of T cells and activated B cells; damages the  C, R R
BBB and the integrity of the endothelium of brain vessel; 
modulates the electrophysiological behavior of neurons
IL-4 Th2 Proliferation and differentiation of activated B cells;  R? R
promotes clonal expansion of specific B cells
IL-6 Mainly Th2 Extremely pleiotropic cytokine influencing antigen-specific  C, R C, R
immune responses and inflammatory reactions; stimulates 
synthesis of ACTH; hematopoietic
IL-10 Th2 Inhibits the synthesis of a number of cytokines such as  C, R C, R
IFN-γ and IL-2 in Th1 cellsCytokines and psychiatric symptoms
Sickness behavior
The IL-1 receptor was the first cytokine-related structure
detected in the brain.
125,126 In 1988, the group led by
Dantzer demonstrated the functional relevance of IL-1
and its receptor in the brain:IL-1 injected into the brain
of rats induced conditioned taste aversion.
127 In the same
year, the effect of another cytokine,TNF-α, was intro-
duced,when the group of Plata-Salaman showed the sup-
pressing effect of IL-1 and TNF-α on feeding behavior.
128
Later,it was shown that peripherally administered LPS
induces the expression of IL-1α, IL-1β, TNF-α, and 
IL-6 in brain macrophages and microglia.
129-131This effect
seems to be a key mechanism in the induction of non-
specific sickness symptoms including fever, anorexia,
hyperalgesia,and the so-called sickness behavior,which
is characterized by weakness,malaise,listlessness,cogni-
tive impairment,depressed mood,lethargy,and reduced
feeding behavior.
132
Behavioral changes during cytokine therapy
The first indication of a role for cytokines in sickness
behavior in humans came from clinical trials in which
recombinant or purified cytokines were used to treat spe-
cific cancers or chronic viral infections such as hepatitis
B or C.The syndrome produced by these inflammatory
mediators resembled those seen in patients with major
depression (MD).
133
The first report on the sickness behavior–inducing effect
of cytokines was published by Smedley and colleagues,
who treated patients with advanced locally recurrent
breast cancer with a high dose (160 MU/week) of IFN-α.
15
Within 1 h of administration,they observed influenza-
like symptoms,which 1 week later were superseded by
lethargy,anorexia,and nausea,with a consequent loss of
weight in most patients.Other side effects included pro-
found somnolence,confusion,and paresthesia.Low-dose
IFN-α therapy (3-5 MU three times a week) induces less
severe psychiatric symptoms such as irritability and
depression accompanied by impaired concentration,lack
of motivation,sleep disturbances,and decreased libido.
134
Depressive symptoms induced by IFN-α or IL-2 therapy
were described to be related to a decreased tryptophan
availability.
135
Not only sickness behavior,but also schizophrenia-like
symptoms including agitation,cognitive impairment,dis-
orientation,delusions,and hallucinations are induced by
IL-2 and IFN-α.
136,137 Denicoff and colleagues were the
first to report dose- and time-related psychiatric side
effects in cancer patients treated with recombinant IL-2
that ranged from brief to severe agitation and combat-
iveness,requiring antipsychotic therapy.
138
Besides the observation in patients suffering from malig-
nancies or chronic inflammatory diseases,experimental
data in healthy humans confirmed that cytokines,partic-
ularly TNF-α and IL-6,induce depressed mood,anxiety,
and memory impairment.
139
Major depression
The observations described above led to the hypothesis
that sickness behavior may serve as a model for the
immune-related pathophysiology of major depression
(MD).
132 In fact,there is a large body of evidence for an
altered immune response in depressed patients.
As described above, IFN-γ is a characteristic marker of
Th1 cells. IFN-γ is produced in higher amounts by lym-
phocytes of patients with MD than by those of healthy
controls,
140 and higher plasma levels of IFN-γ in
depressed patients,accompanied by lower plasma tryp-
tophan availability, were described.
141,142 This gives addi-
tional evidence for a possible link between the Th1-like
cytokine IFN-γ and the IDO-related reduction in 5-HT
availability in the CNS of depressed patients. Given 
a functional relationship among the Th1-dominated
immune system,the serotonergic system,and MD,anti-
Basic research
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Figure 2. The essential amino acid tryptophan is converted either into the
neurotransmitter serotonin, or into the neuroactive metabolite
kynurenine, which is further degraded to quinolinic acid. The
rate-limiting enzyme in the kynurenine pathway, indoleamine-
2,3-dioxygenase (IDO), and kynurenine hydroxylase (KYN-
Hydrox) are activated by the cytokine interferon gamma (IFN-γ).
IDO
KYN-Hydrox
IFN-γ
Tryptophan
Kynurenine
+
+
Quinolinic
acid
Serotonin
5-Hydroxyindole
acetic aciddepressant therapy should be adequate to induce a Th1
to Th2 shift.There are indeed some reports demonstrat-
ing the potency of antidepressants to significantly reduce
the IFN-γ/IL-10 ratio in vitro
143 and to suppress the Th1
response in patients.
144
The most frequently investigated immune parameter in
patients suffering from MD is IL-6.Most of the publica-
tions report a marked increase of in vitro IL-6 produc-
tion
145 or serum IL-6 levels in depressed patients.
146-151
Since IL-6 is a prominent marker of monocyte activity,a
predominant activation of the monocyte/macrophage
system in MD was hypothesized.
152 IL-6 may be involved
in the modulation of the HPA axis.
153Activation of the
HPA axis is one of the best-documented changes in
MD.
154 Furthermore, the relationship between psycho-
logical or physical stress and an enhanced IL-6 secretion
in the peripheral immune system seems to be well estab-
lished.
155-158 Impaired stress coping is often observed in
depressed patients.Thus,the high number of reports of
elevated peripheral IL-6 levels in MD patients may be
related to psychological stress.
On the other hand,there is evidence for a relationship
between high peripheral IL-6 levels and elevated CNS 
5-HT availability.IV or IP administration of IL-6 induced
not only an activation of the HPA axis, but also an
increase in brain tryptophan and 5-HT metabolism,
whereas the norepinephrine metabolism was unaf-
fected.
113Accordingly,IL-6 seems to mediate the activa-
tion of the HPA axis and the 5-HT CNS after adminis-
tration of the endotoxin LPS.
112 Thus, elevated plasma
levels of IL-6 do not fit with the hypothesis of a 5-HT
deficiency in MD.Rather,it should be recognized that an
inherent heterogeneity exists in the etiology of depres-
sion and different neurotransmitter systems may be dis-
turbed.
On the basis of the commonly accepted idea that MD
may be a heterogeneous group of disease entities, the
group of Arolt and Rothermundt investigated the dif-
ference between melancholic and nonmelancholic MD
regarding their cytokine expression patterns.
159 They
detected profound differences between these diagnos-
tic subgroups:nonmelancholic patients showed increased
counts of leukocytes, lymphocytes, and natural killer
(NK) cells in the acute stage of disease and after 2 and 4
weeks of treatment.However,their in vitro production
of the cytokines IL-2,IL-10,and IFN-γ was unchanged
compared with that of healthy controls. Melancholic
patients on the other hand demonstrated normal cell
counts,but a decreased in vitro production of IL-2,IFN-γ,
and IL-10 during the acute stage of disease. Following
clinical improvement,cytokine production patterns nor-
malized in these patients.
Schizophrenia
A pathophysiological role of cytokines is also discussed
in the other major psychiatric disorder,schizophrenia.
The reports of the psychotic symptoms inducing effects
of IL-2 in cancer patients attracted attention of this Th1-
like cytokine to the immunopsychiatric schizophrenia
research.Early studies reported elevated IL-2 levels in
cerebrospinal fluid of schizophrenia patients,
160,161 but oth-
ers failed to replicate these intriguing findings.
162-165 IL-2
levels in serum were reported to be either increased
166 or
decreased.
167
A significant decrease in the production of IL-2 by
peripheral lymphocytes is one of the best-replicated
immunological findings in schizophrenia.
168,169 Some data
suggested that decreased IL-2 production is associated
with acute illness in patients who produce elevated
amounts of autoantibodies,or in patients with later age
at onset,
170-172 though there are again some contradictory
findings.
173,174
The group led by Arolt repeatedly found a markedly
decreased in vitro production of IFN-γ,but the associa-
tion with psychopathological variables was not consis-
tently replicable.
168,175,176
Mittleman et al examined the cerebrospinal fluid of juve-
nile first-onset schizophrenia patients in comparison to
juvenile patients with obsessive-compulsive disorder or
attention deficit hyperactivity,and reported a reduction
to undetectable levels of IFN-γ in most of the schizo-
phrenia patients,in contrast to the measured levels in the
other neuropsychiatric patients.On the other hand,lev-
els of the Th2 cytokine IL-4 were only detectable in cere-
brospinal fluid of juvenile patients with schizophrenia,
but were too low to be detected in that of the control
groups.
165
As stated above,the IL-10 gene was identified as a pos-
sible susceptibility gene for schizophrenia.It is remark-
able that administration of clozapine at a 10
-4 M con-
centration markedly reduces the in vitro production of
IL-10 by stimulated lymphocytes.
177 This may indicate
the possible relevance of IL-10 in the pathophysiology
of schizophrenia. IL-10 was in fact reported to be
increased in the serum of schizophrenia patients.
178Two
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147out of three in vitro stimulation studies showed no dif-
ference between schizophrenia patients and healthy
controls,
174,179 while one described a highly significant
increase in IL-10 production of chronically ill schizo-
phrenia patients, compared with healthy controls, with
medium levels in the subgroup of paranoid schizophre-
nia patients.
180
Peripheral administration of IL-6 induces increased
dopamine and 5-HT turnovers in the hippocampus and
frontal cortex of rodents,without influencing the metab-
olism of norepinephrine.
114Within the brain,IL-6 is pro-
duced not only by glial cells,but also by neurons.
181Thus,
IL-6 is of interest in schizophrenia research.A remark-
able number of publications report significantly
increased serum IL-6 levels in schizophrenia patients.
Some of them additionally found an association with
duration of illness,negative symptoms,and treatment-
resistant schizophrenia.
150,166,182-187 However,these data are
limited by several confounding factors influencing serum
IL-6 levels, such as smoking, gender, age, body mass
index,and ongoing infections,as well as clozapine treat-
ment.
188,189
In summary, the whole body of data on cytokines in
schizophrenia indicates a relatively reduced production
of Th1-like cytokines and a more pronounced production
of Th2-like cytokines.This cytokine profile,together with
the numerous findings of increased levels of circulating
antibodies and other immunological data,prompted us
to the hypothesis of a Th1 to Th2 shift in schizophre-
nia.
190,191A cytokine dysbalance like a Th2 predominance
may be related to a disturbed neurodevelopment and
brain maturation,as it is proposed as pathomorphologic
correlate of schizophrenia.
192
Concluding remarks
The interdisciplinary approach of PNI has led to an inte-
grative view of the immune system and the nervous sys-
tem.Meanwhile,it is commonly accepted that not only
does the CNS influence the immune reaction, but also
that the immune system,particularly via its hormones—
the cytokines—acts on brain function and behavior.
There is ample evidence for the contribution of cytokines
in psychiatric symptoms,syndromes,and disorders,and
the involvement of the immune system fits to other com-
monly accepted etiopathological concepts like the neuro-
developmental hypothesis of schizophrenia.
Genetic research gives further evidence for the possible
involvement of the cytokine system especially in schizo-
phrenia.However,the exact mechanisms of (inter)action
must be elucidated in further investigations. Immuno-
psychiatrists may learn from somatic disorders like the
systemic lupus erythematosus (SLE),an inflammatory
disease affecting many organ systems including the CNS.
The CNS affection in SLE encompasses a wide spectrum
of neurological and psychiatric features including demen-
tia,anxiety,depression,and psychosis,
193 and the causative
role of cytokines, predominantly TNF-α, for the neu-
ropsychiatric symptoms of SLE was proposed.
134Another
aspect for future research derives from first therapy
approaches in psychiatric disorders based on immuno-
logical considerations.The report of the therapeutic effi-
cacy of a COX-2 inhibitor in schizophrenia
194 has partic-
ularly demonstrated the importance of immunological
research in psychiatric disorders.
Thus, the new paradigm of brain–immune interaction
appears to evoke new research and treatment strategies. ❏
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Citoquinas: neurofisiología, neuropsicología
y síntomas psiquiátricos
La investigación reciente ha sobrepasado los anti-
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que los neurotransmisores y neuropéptidos tenían
un papel exclusivo en la transducción de señales en
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cia que sugiere que las proteínas de señales del sis-
tema inmune –las citoquinas– también participan en
la modulación de la conducta y en la inducción de
síntomas psiquiátricos. Este artículo entrega una
visión panorámica acerca de la naturaleza de las cito-
quinas y los mecanismos propuestos de la interacción
entre la inmunidad y el cerebro. Se discute el papel
de las citoquinas en síntomas, síndromes y trastornos
psiquiátricos como la conducta de enfermedad, la
depresión mayor y la esquizofrenia, como también
recientes hallazgos inmunogenéticos.
Cytokines et symptômes psychiatriques
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